Subsidiary’s application for clinical trial registration of GenSci144 tablets for domestic production approved
July 31, 2026
Source: drugdu
41
People's Finance News, July 30th - Changchun High & New Technology Industries Group Co., Ltd.(000661) announced on July 30 that its subsidiary, Jinsai Pharmaceutical, recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration, and the application for registration of the domestic production of GenSci144 tablets by Jinsai Pharmaceutical has been approved.
GenSci144 tablets are an oral small molecule inhibitor targeting the neutral amino acid transporter SLC6A19, independently developed by Jinsai Pharmaceutical. It is registered as a Class 1 chemical drug and is intended for the treatment of chronic kidney disease (CKD).
https://finance.eastmoney.com/a/202607303826738322.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- While Da Vinci Remains in “Remote Control” Mode, Cornerstone Robotics Has Evolved to “Autonomous Operation”—A Technological Leap for Domestic Surgical Robots July 31, 2026
- Carbamazepine Extended-Release Tablets (II) Receive Drug Registration Certificate July 31, 2026
- Levocarnitine Oral Solution Receives Drug Registration Certificate July 31, 2026
- Application for drug registration and marketing authorization of dapagliflozin tablets accepted July 31, 2026
- China Biopharmaceutical and Indonesia’s Tempo Scan establish a joint venture with China Biopharmaceutical holding a 51% stake to expand the Southeast Asian pharmaceutical market July 31, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
